Skip to content

Study of Endothelial Cell Condition After Cataract Surgery Performed Using Capsulorhexis or ZEPTO

A Prospective Randomized Controlled Masked Study of Endothelial Cell Condition After Cataract Surgery Performed Using Manual Capsulorhexis or the ZEPTO Precision Capsulotomy System

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04882189
Acronym
ZEPTO
Enrollment
80
Registered
2021-05-11
Start date
2021-08-23
Completion date
2022-05-30
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Cell Density Loss

Brief summary

This study will use images of the subjects' corneal endothelium obtained using non-invasive specular microscopy to obtain corneal endothelial cell density, the coefficient of variation in endothelial cell size, and the percentage of hexagonal endothelial cells following routine cataract surgery performed using the standard method of manual capsulorhexis compared to cataract surgery performed using Zepto Precision Capsulotomy System.

Interventions

DIAGNOSTIC_TESTImaging

Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.

Sponsors

Centricity Vision, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects consenting to undergoing phacoemulsification and IOL implant surgery for the treatment of symptomatic age-related lens cataract, and then electing to undergo the study, * Subjects must be willing and able to return for scheduled treatment and follow-up examinations at 1 and 3 months.

Exclusion criteria

* Pre-existing corneal endothelium pathology * Presence of guttae * Narrow angle glaucoma or advanced glaucoma * Psuedoexfoliation * Zonular abnormalities * Corneal endothelial cell density less than 1800 cells/mm2 * Uveitis * Anterior chamber depth less than 2.5mm or greater than 3.75mm * Cataract grade LOCS II \> 3 * Posterior polar cataract * Planned implantation of IOL \> 25D * Prior ocular surgery in the study eye * History of medications with potential corneal endothelial cell toxicity * Any condition that in the surgeon's judgement should exclude the subject from study enrollment. * Current participation in another drug or device clinical study, or participation in such a clinical study within the prior six months and during the duration of the current study

Design outcomes

Primary

MeasureTime frameDescription
Endothelial Cell Density Loss3 monthsPost Cataract Surgery

Secondary

MeasureTime frameDescription
Endothelial Cell Density Loss1 monthPost Cataract Surgery
Coefficient of Variation in Endothelial Cell Size1 and 3 monthsPost Cataract Surgery
% of hexagonal cells1 and 3 monthsPost Cataract Surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026